AI
Wednesday, August 29, 2012 10:57:29 AM
ARQL tanker
ArQule plunges 23% on drug safety concern
BOSTON (MarketWatch) -- Shares of ArQule Inc. ARQL -25.69% plunged 23% to $5.15 on Wednesday on safety concerns about its drug candidate tivantinib for the treatment of lung cancer. In a federal filing made Tuesday, ArQule said that its Japanese development partner, Kyowa Hakko Kirin Co., has temporarily suspended a Phase III clinical trial testing tivantinib in combination with the lung-cancer therapy Tarceva over concerns that some of the patients had developed interstitial lung disease. As of Wednesday, shares of ArQule are down 9% from the start of the year.
ArQule plunges 23% on drug safety concern
BOSTON (MarketWatch) -- Shares of ArQule Inc. ARQL -25.69% plunged 23% to $5.15 on Wednesday on safety concerns about its drug candidate tivantinib for the treatment of lung cancer. In a federal filing made Tuesday, ArQule said that its Japanese development partner, Kyowa Hakko Kirin Co., has temporarily suspended a Phase III clinical trial testing tivantinib in combination with the lung-cancer therapy Tarceva over concerns that some of the patients had developed interstitial lung disease. As of Wednesday, shares of ArQule are down 9% from the start of the year.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
